ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO540

Severe Hypomagnesemia Due to Renal Magnesium Wasting in Patient with HNF1B Mutation and Pseudogout

Session Information

Category: Fluid, Electrolytes, and Acid-Base Disorders

  • 1102 Fluid, Electrolyte, and Acid-Base Disorders: Clinical

Authors

  • Che, Michael, University of Ottawa, Faculty of Medicine, Division of Nephrology, Ottawa, Ontario, Canada
  • Magner, Peter, University of Ottawa, Faculty of Medicine, Division of Nephrology, Ottawa, Ontario, Canada
  • Hesketh, Caitlin, University of Ottawa, Faculty of Medicine, Division of Nephrology, Ottawa, Ontario, Canada
  • Brown, Pierre-Antoine, University of Ottawa, Faculty of Medicine, Division of Nephrology, Ottawa, Ontario, Canada
Introduction

Hepatocyte nuclear factor 1β (HNF1B) is a transcription factor that is essential for proper development of the kidney and pancreas. Here, we report a case of severe hypomagnesemia and cystic kidney disease due to HNF1B mutation in a patient with pseudogout.

Case Description

A 41-year-old female with hypothyroidism and frequently flaring pseudogout with severe chondrocalcinosis in multiple joints was referred to nephrology for assessment of hypomagnesemia refractory to oral magnesium (Mg) supplementation. There was no history of gastrointestinal losses, offending medications, or family history of hypomagnesemia.

Plasma Mg was 0.35 mmol/L and she had metabolic alkalosis with total CO2 of 32 mmol/L but normal plasma calcium, potassium, sodium, phosphate, creatinine, and parathyroid hormone. Plasma Mg was very low for at least one year prior to nephrology assessment. Urine fractional excretion of Mg (FEMg) was 3.9%, consistent with renal Mg wasting.

Genetic testing for hereditary causes of renal Mg wasting revealed a heterozygous pathogenic HNF1B gene variant, identified as 1.26 Mb deletion, seq[GRCh37] del(17)(q12),chr17:g.34842466_36104935del. An abdominal CT scan revealed a congenital agenesis variant of the dorsal pancreas and multiple left renal cysts, both in keeping with her HNF1B mutation.

She was treated with amiloride, titrated to 15 mg BID, to reduce renal Mg wasting, in addition to oral Mg glycinate supplementation, but her Mg continued to remain low. Consequently, she was also started on IV Mg sulfate 5 mg weekly. Plasma Mg improved slightly to 0.5 mmol/L but FEMg remained high at 5.5%. Dapagliflozin 10 mg daily was further added and FEMg improved to 2.6%. Her plasma Mg fluctuates depending on timing relative to weekly IV Mg infusion but has been as normal as 0.9 mmol/L. She continues on oral Mg supplementation, weekly IV Mg infusions, and amiloride and dapagliflozin.

Discussion

Severe hypomagnesemia is known to cause increased chondrocalcinosis likely contributing to the patient’s poorly controlled pseudogout. Numerous renal manifestations are associated with HNF1B mutations including cystic kidney disease and renal Mg wasting as demonstrated in this case. Hypomagnesemia when associated with HNF1B variants may be severe, refractory to oral Mg supplementation, and consequently may benefit from IV Mg infusions and diuretic therapy.